The 36-month beta value for AVXL is at 0.71. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AVXL is 82.12M, and currently, shorts hold a 26.55% of that float. The average trading volume for AVXL on January 15, 2025 was 1.81M shares.
AVXL) stock’s latest price update
The stock price of Anavex Life Sciences Corporation (NASDAQ: AVXL) has plunged by -0.76 when compared to previous closing price of 10.55, but the company has seen a -20.14% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-13 that Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX®2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good comparative safety profile and no associated neuroimaging adverse events.
AVXL’s Market Performance
Anavex Life Sciences Corporation (AVXL) has experienced a -20.14% fall in stock performance for the past week, with a 28.00% rise in the past month, and a 94.61% rise in the past quarter. The volatility ratio for the week is 10.39%, and the volatility levels for the past 30 days are at 11.95% for AVXL. The simple moving average for the last 20 days is -3.01% for AVXL stock, with a simple moving average of 72.18% for the last 200 days.
Analysts’ Opinion of AVXL
Many brokerage firms have already submitted their reports for AVXL stocks, with Cantor Fitzgerald repeating the rating for AVXL by listing it as a “Neutral.” The predicted price for AVXL in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on December 06, 2022 of the previous year 2022.
Berenberg, on the other hand, stated in their research note that they expect to see AVXL reach a price target of $40. The rating they have provided for AVXL stocks is “Buy” according to the report published on June 23rd, 2022.
BTIG Research gave a rating of “Buy” to AVXL, setting the target price at $35 in the report published on September 23rd of the previous year.
AVXL Trading at 12.16% from the 50-Day Moving Average
After a stumble in the market that brought AVXL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.50% of loss for the given period.
Volatility was left at 11.95%, however, over the last 30 days, the volatility rate increased by 10.39%, as shares surge +26.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +83.36% upper at present.
During the last 5 trading sessions, AVXL fell by -20.14%, which changed the moving average for the period of 200-days by +106.92% in comparison to the 20-day moving average, which settled at $10.79. In addition, Anavex Life Sciences Corporation saw -2.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVXL starting from Donhauser Peter D.O., who purchase 2,835 shares at the price of $3.64 back on Jun 14 ’24. After this action, Donhauser Peter D.O. now owns 5,000 shares of Anavex Life Sciences Corporation, valued at $10,319 using the latest closing price.
Thomas Steffen, the Director of Anavex Life Sciences Corporation, purchase 5,000 shares at $4.52 during a trade that took place back on May 15 ’24, which means that Thomas Steffen is holding 5,000 shares at $22,600 based on the most recent closing price.
Stock Fundamentals for AVXL
The total capital return value is set at -0.42. Equity return is now at value -32.81, with -29.66 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 8.86.
Conclusion
In conclusion, Anavex Life Sciences Corporation (AVXL) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
